Health Technologies
and Biotechnology
We shape the future of medicine through our strategic investments in global funds focused on health technologies and advanced biotechnology. We merge our capital strength and global network with high-potential funds transforming life sciences.
Investing in
Healthcare Funds.
Maksut Konyar Holding positions its presence in health technologies and biotechnology by investing in next-generation global funds focused on extending human lifespan, improving the quality of life, and preventive medicine.
This strategic approach aims to support a broad innovation network extending from AI-supported drug discoveries to multi-omics data platforms with capital strength. The Holding acts not merely as a financial investor in this field, but as a strategic umbrella power shaping the growth of the global health ecosystem through the funds it invests in.
Investment
Fund
ANATOLIA HEALTH-TECH
Anatolia Health-Tech Investment Fund is a structured investment fund of approximately 30 million USD, focusing on life sciences and longevity.
The fund invests in selected companies operating in high-growth areas such as data-driven health technologies, multi-omics platforms, and cell/gene therapies.
Its investment strategy is built on creating long-term value by incorporating companies with a strong scientific foundation, high commercial potential, and the ability to scale globally into the portfolio at an early stage. In this context, the fund is managed with a rigorous due diligence process, an international investment committee, and strict KPI-based performance management.
The fund's investment approach goes beyond providing capital, encompassing active support for portfolio companies in critical areas such as corporate governance, production infrastructure (GMP/QMS), market access, and global growth strategies.
Portfolio
Companies
Trustlife Therapeutics
AI-Powered Drug Discovery
Trustlife is an R&D company managing next-generation drug discovery and development processes end-to-end utilizing systems biology and AI-supported platforms. With 16 active drug development programs, the company has projects ready to advance to clinical stages in areas with high market potential such as Alzheimer's, liver cancer, and metabolic diseases. Supported by an international office network (USA, UK, Turkey) and a strong scientific staff, Trustlife offers a scalable model that accelerates traditional drug development processes and optimizes costs.
Portfolio
Companies
Phenome Longevity
Data-Driven Preventive Health Platform
Phenome Longevity is an income-generating, internationally operating health technology platform built on multi-omics data generation and analysis. Having analyzed over 100,000 biological samples to date, the company develops solutions for the early diagnosis and prevention of diseases using AI-supported systems. Through its “1 Million Phenome Initiative,” it aims to establish large-scale datasets in over 15 countries by 2030. Thanks to its partnerships with global health institutions and technology leaders, Phenome secures a strong position in the data-driven health ecosystem.
Portfolio
Companies
TCT Health
Production Infrastructure in Cell and Gene Therapies
TCT Health is a biotechnology company operating in the field of cancer-focused cell and gene therapies, positioned as one of Turkey's first production platforms. The company aims to make advanced treatment methods, primarily CAR-T cell therapies, more accessible and cost-effective. Backed by international technology partnerships and hospital networks, TCT operates with the goal of becoming a regional biotechnology hub for Turkey, the Middle East, and surrounding geographies.
